RRGENER

RRGENER (Shanghai Dingxin Gene Technology Co., Ltd.) was jointly founded by a senior management team and a scientist team in the biopharmaceutical field. The founding team has over 15 years of experience in biomedicine and gene therapy-related research. As a biopharmaceutical innovation R&D company focusing on gene therapy drug development, RRGENER is committed to building a world-class gene therapy R&D platform and continuously developing First-in-class and Best-in-class gene therapy drugs. RRGENER has an 800-square-meter gene therapy R&D laboratory in the FT-ONE Life Science Park in Shanghai Waigaoqiao Free Trade Zone. It possesses efficient and stable platforms for plasmid preparation, AAV vector suspension culture, RNA modification, downstream purification, and non-viral delivery technology development. Based on technologies such as AAV vector-based gene therapy, mRNA vaccines, and siRNA gene silencing, RRGENER focuses on the treatment of rare diseases and chronic diseases in ophthalmology, otology, cardiovascular, oncology, and CNS fields, providing patients with innovative gene therapy opportunities aimed at lifelong benefits or even cures.